4BASEBIO PLC

Director's Dealing • Nov 29, 2024

National Storage Mechanism | Additional information

4basebio Plc - Director's Dealing

PR Newswire

LONDON, United Kingdom, November 29

29 November 2024

4basebio plc

(“4basebio” or the "Company")

Director’s Dealing

29 November 2024 – 4basebio PLC (AIM: 4BB) (“4basebio” or the “Company”), which develops and commercialises the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announces that it was informed by Dr. Heikki Lanckriet , CEO of the Company, that he acquired ordinary shares in the Company through the market as follows: 

Name	Number of Shares Acquired	Price per Share (p)	Shareholding Following Acquisition	Shareholding as a Percentage of Issued Share Capital
Heikki Lanckriet	12,000	1,315p	1,115,288	7.27%

The issued share capital of the Company comprises 15,477,395 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

Enquiries

4basebio PLC Dr. Heikki Lanckriet	+44 (0)1223 967 943
Nominated Adviser Cairn Financial Advisers LLP Jo Turner / Sandy Jamieson / Ed Downes	+44 (0)20 7213 0880
Joint Corporate Broker RBC Capital Markets Rupert Walford / Kathryn Deegan	+44 (0)20 7653 4000
Joint Corporate Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks	+44 (0)20 7220 0500

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Dr. Heikki Lanckriet
2	Reason for notification
a.	Position/Status	CEO
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	4basebio plc
b.	LEI	213800E2DX9EAIUNCB30
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: GB00BMCLYF79
b.	Nature of the transaction	Acquisition of ordinary shares
			Price(s) per share (p)	Volume(s)
1,315p	12,000
d.	Aggregated information - Volume - Price	- 12,000 - 1,315 pence per share
e.	Date of the transaction	28/11/2024
f.	Place of the transaction	London Stock Exchange, AIM

---

---